Serina Therapeutics Inc. Common Stock (SER)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. Serina does not fit that mold today. It is a 16-employee clinical-stage biotech with no meaningful revenue. In fiscal 2025, the year ended 2025-12-31, revenue was $130,000 and net loss was $19.2M. That compares with $56,000 of revenue and an $11.1M loss in fiscal 2024. Fiscal 2023 showed $3.2M of revenue and $5.3M of net income, but the Lynch category is correctly TURNAROUND — loss in the latest year after earlier profits. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $6.4M, or $0.55 per diluted share. Trailing free cash flow was -$21.2M, giving a FairStock FCF yield of -45.9%. At the 2026-10-13 close of $1.82 and $46.2M market cap, FairStock shows P/E -0.97, P/B 2.46, ROE -207.94%, ROCE -92.30%, and D/E 0.20. The negative P/E is not useful; the cash burn is the real issue. Piotroski 1/9 and Altman Z 0.74 point to financial fragility. The moat is unproven; value rests on SER 252 in Phase 1 and POZ-lipids. I would want clinical validation, partnership cash, and a much lower burn before calling this a business rather than a lottery ticket.

In plain English: Serina Therapeutics is a small biotech company developing experimental drugs for Parkinson's disease and pain. It has very little revenue, loses money, and burns cash. At $1.82, the price does not look cheap relative to its weak financial results; it is a speculative clinical-stage story that depends on trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer